About Beijing Centergate Technologies Company

The company was founded in 1999 and listed on the Shenzhen Stock Exchange. In 2015, the company's industrial pattern gradually changed from “technology real estate+medicine” to a development and management strategy centered on “medicine and health”. In August 2018, the company was approved by the regulatory authorities, and the industry classification was changed from “comprehensive” to “pharmaceutical manufacturing”, and the strategic transformation was initially successful. In August 2021, the company adjusted its development strategy and further focused on positioning, and plans to establish an innovative pharmaceutical industry group focusing on the pharmaceutical field. The company's business is mainly divided into biomedicine and health products business, nursing care business, commercial concrete business and other businesses. The company's main products include zimusaponin BII and capsules, bifonazole raw materials, naloxone hydrochloride injections, glipyrazine dispersible tablets, metoprolol succinate raw materials, ambroxol hydrochloride injections, toranisetron mesylate injections, silidiol tablets, phenylcyclononyl hydrochloride tablets, naloxone hydrochloride injections, huxacin tablets, tramadol hydrochloride injections Aminophenol tramadol tablets, tramadol hydrochloride raw materials, home care services, health management, health consultation, preventive health consultation, traditional Chinese medicine medical services, manufacturing Sale of commercial concrete and cement products, management of electronic stores, property management services, hotel services, etc.